Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR: Efficacy and Safety of Efdamrofusp Alfa (IBI302) in nAMD
NCT05972473Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Sep 2023
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of efdamrofusp alfa in neovascular age-related macular degeneration (NVAMD), sponsored by Innovent Biologics. Started Sep 2023; status: active, not recruiting.
02
Drugs
efdamrofusp alfa
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05972473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972473.